旺山旺水-B(02630)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02630 旺山旺水-B

已收盘 11-04 16:08:09

80.000

+3.250

+4.23%

最高80.000	最低76.000	成交量8.40万
今开77.500	昨收76.750	日振幅5.21%
总市值134.40亿	流通市值133.60亿	总股本1.68亿
成交额649.91万	换手率0.05%	流通股本1.67亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02630","market":"HK","secType":"STK","nameCN":"旺山旺水-B","latestPrice":80,"timestamp":1793779689107,"preClose":76.75,"halted":0,"volume":84000,"delay":0,"changeRate":0.04234527687296417,"floatShares":167000000,"shares":168000000,"eps":-2.7410076418528746,"marketStatus":"已收盘","change":3.25,"latestTime":"11-04 16:08:09","open":77.5,"high":80,"low":76,"amount":6499120,"amplitude":0.052117,"askPrice":80,"askSize":1400,"bidPrice":78,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.22662520691062,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793842200000},"marketStatusCode":5,"adr":0,"listingDate":1762358400000,"exchange":"SEHK","adjPreClose":76.75,"openAndCloseTimeList":[[1793755800000,1793764800000],[1793768400000,1793779200000]],"volumeRatio":0.560368,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02630","defaultTab":"news","newsList":[{"id":"1195620506","title":"旺山旺水-B回购7.36万股股份，总额约568.63万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195620506","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195620506?lang=zh_cn&edition=full","pubTime":"2026-11-04 18:47","pubTimestamp":1793789234,"startTime":"0","endTime":"0","summary":"苏州旺山旺水生物医药股份有限公司于2026年11月4日公告，宣布在香港联交所场内回购73,600股H股，约占该次回购前公司已发行股份总数的0.0442%。回购价格区间为每股76港元至79.50港元，合计付出约568.63万港元。本次股份回购后，公司于2026年11月4日的已发行股份数变更为166,480,200股，库存股份数增至417,600股，总股份数依旧为166,897,800股。公司于2026年6月30日获股东大会批准回购授权，可购买最多6,667,713股股份。公司确认本次回购行为符合相关上市规则及适用法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"旺山旺水-B回购7.36万股股份，总额约568.63万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680325630","title":"旺山旺水-B(02630)11月4日斥资568.63万港元回购7.36万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680325630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680325630?lang=zh_cn&edition=full","pubTime":"2026-11-04 18:41","pubTimestamp":1793788900,"startTime":"0","endTime":"0","summary":"智通财经APP讯，旺山旺水-B(02630)发布公告，于2026年11月4日斥资568.63万港元回购7.36万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02630","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112183970","title":"旺山旺水-B公布10月股份变动月报，回购141,000股H股转为库存","url":"https://stock-news.laohu8.com/highlight/detail?id=1112183970","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112183970?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:55","pubTimestamp":1793782544,"startTime":"0","endTime":"0","summary":"苏州旺山旺水生物医药股份有限公司于2026年11月4日发布2026年10月的股份变动月报表，说明本期股本结构及变动情况。报告显示，截至2026年10月31日，公司法定注册股本总额保持在人民币167,597,800元；其中，H股法定注册股本为166,897,800股，非上市普通股法定注册股本为700,000股，均无增减变化。本月内公司通过股份回购将141,000股H股转为库存股，回购价格为每股港币75.1413，回购日期为2026年10月30日。截至10月底，公司股本总数保持相对稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103660826","title":"旺山旺水-B：11月3日回购42,200股，耗资约336.24万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103660826","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103660826?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:15","pubTimestamp":1793704545,"startTime":"0","endTime":"0","summary":"苏州旺山旺水生物医药股份有限公司于2026年11月3日在香港联交所场内回购股份，回购数量为42,200股，占公司原已发行股本约0.0253%。每股回购价格介乎每股75.65港元至80.50港元，合计耗资约336.24万港元。公司曾于2026年6月30日通过购回授权，最多可购回6,667,713股；截至本次回购，合计已在证券交易所购回344,000股，占授权当日公司已发行股本总数约0.5159%。公司确认已遵守香港联合交易所有限公司的相关上市规则及相关法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"旺山旺水-B：11月3日回购42,200股，耗资约336.24万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155430528","title":"旺山旺水-B回购16.08万股，耗资约1,267.21万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155430528","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155430528?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:45","pubTimestamp":1793623558,"startTime":"0","endTime":"0","summary":"苏州旺山旺水生物医药股份有限公司于2026年11月2日公告，已在香港联交所场内回购股份。根据公告，该公司于2026年11月2日回购160,800股H股，约占回购前已发行股本的0.0964%，每股回购价介乎每股75.40港元至79.80港元，合计支出约1,267.21万港元。回购完成后，公司已发行股本由166,756,800股变更为166,596,000股，库藏股数量相应增加至301,800股。公告显示，公司购回授权于2026年6月30日获通过，授权总额为6,667,713股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"旺山旺水-B回购16.08万股，耗资约1,267.21万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680752482","title":"旺山旺水-B(02630)11月2日耗资约1267.21万港元回购16.08万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680752482","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680752482?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:42","pubTimestamp":1793623374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，旺山旺水-B(02630)公布，2026年11月2日耗资约1267.21万港元回购16.08万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02630","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680781687","title":"港股异动 | 旺山旺水-B(02630)盘中涨超5% 接获包含控股股东在内的全体IPO前投资者自愿延长禁售期","url":"https://stock-news.laohu8.com/highlight/detail?id=2680781687","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680781687?lang=zh_cn&edition=full","pubTime":"2026-11-02 10:00","pubTimestamp":1793584833,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，旺山旺水-B(02630)盘中涨超5%，截至发稿，涨3.45%，报78港元，成交额1231.66万港元。消息面上，旺山旺水-B发布公告，近日，本公司接获包含控股股东在内的全体首次公开发售前投资者的通知，据此，基于对公司研发管线价值、获批药品商业化前景及核心管理团队的高度认可，彼等各自承诺自原禁售期届满日期至其后的7个月或4个月的延长禁售期(延长禁售期)期间，不会以任何方式减持彼等各自持有的本公司股份。本公司认为，延长禁售期表明前述股东对本公司的未来前景及长期价值充满信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","KCAI","VXUS","02630","BK1191","KCE","BK4585","REDS","BK4127","FRHC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172499694","title":"旺山旺水-B回购14.1万股股份，总额约1,059.49万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172499694","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172499694?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:15","pubTimestamp":1793358955,"startTime":"0","endTime":"0","summary":"苏州旺山旺水生物医药股份有限公司于2026年10月30日公告，其在香港联交所回购公司股份14.1万股，占回购前已发行股份约0.0845%。回购价介乎每股港币74.00元至76.80元，总涉资约1,059.49万港元。本次回购后，公司已发行股份总数维持为166,897,800股，其中166,756,800股为已发行且不含库存股份，库存股份新增至141,000股。根据2026年6月30日通过的购回授权，公司可回购股份总数为6,667,713股，已回购股份数量占上述授权时公司已发行股份总数的约0.2115%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"旺山旺水-B回购14.1万股股份，总额约1,059.49万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679213810","title":"旺山旺水-B(02630)10月30日斥资1059.49万港元回购14.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679213810","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679213810?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:14","pubTimestamp":1793358889,"startTime":"0","endTime":"0","summary":"智通财经APP讯，旺山旺水-B(02630)发布公告，于2026年10月30日斥资1059.49万港元回购14.1万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02630","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148010645","title":"旺山旺水-B（02630）多名股东自愿延长禁售期 最长至2027年6月","url":"https://stock-news.laohu8.com/highlight/detail?id=1148010645","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148010645?lang=zh_cn&edition=full","pubTime":"2026-10-30 12:25","pubTimestamp":1793334329,"startTime":"0","endTime":"0","summary":"2026年10月30日，旺山旺水-B发布公告称，包括控股股东在内的全部首次公开发售前投资者自愿延长其所持股份的禁售期限。此前，这些股份的原禁售期至2026年11月5日届满。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679689682","title":"旺山旺水-B(02630.HK)：股东自愿延长禁售期","url":"https://stock-news.laohu8.com/highlight/detail?id=2679689682","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679689682?lang=zh_cn&edition=full","pubTime":"2026-10-30 12:22","pubTimestamp":1793334154,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101696637","title":"旺山旺水-B更新9月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1101696637","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101696637?lang=zh_cn&edition=full","pubTime":"2026-10-06 16:46","pubTimestamp":1791276402,"startTime":"0","endTime":"0","summary":"苏州旺山旺水生物医药股份有限公司于2026年10月6日发布截至2026年9月30日的证券变动月报表。公告显示，当月公司股本结构和已发行股份总数保持不变。公司期内并无新增股份发行或股份回购注销。截至2026年9月底，公司的总股本规模保持稳定。公司表示，将继续严格遵守香港联交所《上市规则》及相关法律规范。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192613577","title":"旺山旺水-B2026年中期营收1.32亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192613577","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192613577?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:34","pubTimestamp":1790760840,"startTime":"0","endTime":"0","summary":"旺山旺水-B发布2026年中期报告，数据显示，截至2026年6月30日，公司实现营收1.32亿元，同比增长约693.7%。同期毛利达到1.18亿元，同比上升910.1%，毛利率从上年同期的70.2%提升至89.4%，上涨19.2个百分点。经营活动所用现金净额约为0.58亿元，较去年同期的0.60亿元略有改善。从成本结构看，2026年中期研发费用约0.83亿元，同比下降约16.9%，主要由于以股份基础的薪酬开支减少。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"旺山旺水-B2026年中期营收1.32亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670844343","title":"港股异动 | 旺山旺水-B(02630.HK)午后涨超4% 抗精神分裂症1类新药VV119近日进入II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2670844343","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670844343?lang=zh_cn&edition=full","pubTime":"2026-09-25 14:47","pubTimestamp":1790318865,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670443480","title":"港股异动 | 旺山旺水-B(02630)午后涨超4% 抗精神分裂症1类新药VV119近日进入II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2670443480","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670443480?lang=zh_cn&edition=full","pubTime":"2026-09-25 14:47","pubTimestamp":1790318865,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，旺山旺水-B午后涨超4%。截至发稿，涨4.63%，报84.7港元，成交额683.14万港元。消息面上，近日，旺山旺水1类创新药VV119胶囊正式进入II期临床研究阶段，并已完成首例试验参与者者给药。这标志着VV119的临床开发由早期安全性、耐受性及药代动力学评价进入患者疗效验证阶段，为后续临床开发奠定基础。该研究计划于2027年底完成，相关研究结果将为VV119后续临床推荐剂量确定、开发策略优化以及更大规模关键性临床研究提供重要依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","VXUS","BK4585","BK1191","02630","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157495628","title":"旺山旺水-B 2026年8月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1157495628","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157495628?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:51","pubTimestamp":1788425478,"startTime":"0","endTime":"0","summary":"苏州旺山旺水生物医药股份有限公司于2026年9月3日公布2026年8月股份变动月报表，报告期为2026年8月。报告显示，公司本月无新增发行、购回及注销股份事宜。普通股H股在香港联交所上市部分上月底及本月底的已发行股份数目均为166,897,800股，库藏股数量始终为0股；非上市部分普通股股份数目维持700,000股不变。根据公告，公司已确认符合适用的最低公众持股量要求，且相关发行及变动均遵循香港联交所《上市规则》与法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103011686","title":"旺山旺水-B2026年中期财报：营收1.32亿元，经调整净亏损0.82亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103011686","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103011686?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:27","pubTimestamp":1787912837,"startTime":"0","endTime":"0","summary":"2026年上半年，旺山旺水-B公布的财报显示，公司实现营收1.32亿元，同比增长693.7%。经调整后净亏损为0.82亿元，相比去年同期的1.01亿元，经调整净亏损收窄约18.9%。报告期内，公司毛利率达到89.4%，同比提升19.2个百分点。管理费用为0.61亿元，同比下降约23%，主要归因为股权激励相关支出减少等因素。从业务分项来看，报告期公司收入大幅增长，主要得益于新上市药品的市场表现显著以及许可业务里程碑收入的贡献。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"旺山旺水-B2026年中期财报：营收1.32亿元，经调整净亏损0.82亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662406152","title":"旺山旺水-B(02630)发布中期业绩，股东应占亏损1.22亿元 同比减少29.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662406152","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662406152?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:20","pubTimestamp":1787912445,"startTime":"0","endTime":"0","summary":"智通财经APP讯，旺山旺水-B(02630)发布截至2026年6月30日止6个月中期业绩，该集团取得收入1.32亿元，同比增加693.7%;公司拥有人应占亏损1.22亿元，同比减少29.4%;每股基本亏损0.73元。公告称，收入增加主要由于2025年7月本集团开始商业化一款新药品，该药品销量持续上升，收入增加1.07亿元;及2025年12月本集团与客户正式就VV116新适应症订立许可协议，2026年上半年收取里程碑款项2000万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113162109","title":"财报前瞻｜旺山旺水-B本季度关键财务预测缺失，机构观点暂未形成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1113162109","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113162109?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:50","pubTimestamp":1787280642,"startTime":"0","endTime":"0","summary":"旺山旺水-B将于2026年08月28日发布最新财报，市场对核心财务指标暂无一致预估，投资者关注点集中于收入结构与盈利能力的边际变化。目前未能检索到覆盖旺山旺水-B的机构或分析师最新季度财报前瞻文章，亦无法形成看多或看空的比例判断，相关知名机构观点暂缺。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜旺山旺水-B本季度关键财务预测缺失，机构观点暂未形成一致","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123831636","title":"旺山旺水-B（02630）拟于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1123831636","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123831636?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:40","pubTimestamp":1787042454,"startTime":"0","endTime":"0","summary":"苏州旺山旺水生物医药股份有限公司（股票代码：02630，以下简称“旺山旺水-B”）8月18日公告称，公司董事会将于2026年8月28日（星期五）召开会议。届时，董事会将审议并批准集团截至2026年6月30日止六个月的中期业绩及其发布事宜，同时考虑派发中期股息（如有）并处理其他相关事项。\n公告显示，旺山旺水-B现有董事会成员包括执行董事田广辉博士（亦担任董事长、首席执行官及总经理）及胡天文博士，非执行董事刘浩轩先生，以及独立非执行董事鞠佃文博士、曹新文女士及徐宏喜博士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vigonvita.cn","stockEarnings":[{"period":"1week","weight":-0.0007},{"period":"1month","weight":-0.0548},{"period":"3month","weight":-0.2641},{"period":"6month","weight":-0.009},{"period":"1year","weight":1.3},{"period":"ytd","weight":-0.0623}],"compareEarnings":[{"period":"1week","weight":0.021},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0922},{"period":"6month","weight":-0.1164},{"period":"1year","weight":-0.1006},{"period":"ytd","weight":-0.0821}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州旺山旺水生物医药股份有限公司是一家主要从事发现、开发和商业化小分子药物的中国公司。该公司主要专注于神经精神、生殖健康及病毒感染治疗领域。该公司的产品管线主要包括LV232, TPN102, VV119, VV147, TPN171, VV913, VV116, VV261和VV207。该公司已进入商业化阶段。该公司主要在中国及乌兹别克斯坦经营其业务。","exchange":"SEHK","name":"旺山旺水-B","nameEN":"VIGONVITA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"旺山旺水-B(02630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供旺山旺水-B(02630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"旺山旺水-B,02630,旺山旺水-B股票,旺山旺水-B股票老虎,旺山旺水-B股票老虎国际,旺山旺水-B行情,旺山旺水-B股票行情,旺山旺水-B股价,旺山旺水-B股市,旺山旺水-B股票价格,旺山旺水-B股票交易,旺山旺水-B股票购买,旺山旺水-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"旺山旺水-B(02630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供旺山旺水-B(02630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}